Crossmark

Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel

Crossref DOI link: https://doi.org/10.1186/s12916-022-02244-0

Published Online: 2022-01-31

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gurioli, Giorgia

Conteduca, Vincenza

Brighi, Nicole

Scarpi, Emanuela

Basso, Umberto

Fornarini, Giuseppe

Mosca, Alessandra

Nicodemo, Maurizio

Banna, Giuseppe Luigi

Lolli, Cristian

Schepisi, Giuseppe

Ravaglia, Giorgia

Bondi, Isabella

Ulivi, Paola

De Giorgi, Ugo
License Information

Text and Data Mining valid from 2022-01-31

Version of Record valid from 2022-01-31
More Information

Article History

Received: 6 October 2021

Accepted: 7 January 2022

First Online: 31 January 2022

Declarations

:

: This study (NCT03381326) was approved by the Institutional Review Board of IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy (protocol code: IRST B030), and written informed consent was obtained from all patients.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below